About us
Dianosic is clinical-stage biotech designing transformative long-acting resorbable intranasal solid-dosage forms to overcome the delivery challenges of current chronic respiratory and CNS therapies.
Vision: Transform patients’ lives through intranasal therapeutics for chronic diseases
Mission: Provide a platform of long-acting intranasal solid-dosage forms enabling local and Nose-To-Brain drug delivery, relieving patients from the burden of daily medication.
2026
- Phase I clinical trial initiation in chronic allergic rhinitis. Ongoing discussions with Pharma regarding co-development opportunities.
2025
- Dianosic prepares for launch of its Phase I clinical trial in chronic allergic rhinitis. Confirmation of positive results in N2B (schizophrenia).
- Dianosic closes a €7.8 million equity round led by Aptar alongside Noshaq, Capital Grand Est and Finovam.
2024
- Promising initial preclinical in vivo results in schizophrenia (N2B).
2023
- Dianosic raises €6 million (dilutive and non dilutive) to advance its DIA01-R program in chronic allergic rhinitis and kick off activities in brain diseases (Nose-To-Brain approach)
2022
- Final formulation for DIA01-R in chronic allergic rhinitis.
2021
- Dianosic delivers robust in vitro and initial in vivo data for its platform (respiratory indications).
2020
- Dianosic closes a first €2 million round of financing (dilutive and non dilutive).
2018
- Dianosic starts R&D activities for its platform in respiratory diseases.
2017-2018
- Development of CAVI-T, a minimally invasive solution to improve the treatment of epistaxis.
Origine
- Dianosic is co-founded in July 2017 by Marc Augustin (President), Philippe Bastide (CEO) and Pr Christian Debry (Head of the ENT Dept at the University Hospital of Strasbourg).
Qualified team with complementary profiles
- Seasoned entrepreneur
-
>20 years of experience in Finance and International Development (Stellantis, IBM)
-
Member of the executive committee of the health insurancel company UNEO
-
Merger Acquisition / fundraising advisor (ACM partners)
- Linkedin account: https://bit.ly/3EvE9u1
-
> 20 years of experience in Medtech and Pharma (Pfizer, Johnson & Johnson, Livanova)
-
Business Unit Lead at Acclarent (ENT Division of Johnson & Johnson)
- Expertise in Market Access (pricing & reimbursement), Business Development and Professional Education
- Linkedin account: https://bit.ly/3sRamJv
- 10 years' experience in medical devices and pharmaceuticals (Roche)
- Expertise in quality management & regulatory affairs
- Doctorate in Biology from the University of Strasbourg (CIFRE SANOFI)
- Linkedin account: https://bit.ly/44RT6l2
-
14 years of experience in pharmaceutical development, generics, orphan drugs and combination products
- CMC Regulatory Project Management invariuous companies (INNOTHERA, NOVARTIS, OT4B )
- Expertise in product development and analytical chemistry
- Linkedin account: https://bit.ly/44GfrSh
- 10 years' experience in research projects (University of Strasbourg)
- Expertise in in vivo studies
- PhD in Pharmacology + Diploma in Clinical Research
- Linkedin account: https://bit.ly/3sQRomk
- Over 20 years' career in the healthcare industry
- Solid experience in general management, operational strategy, business development, marketing and sales management at international level, across regions (Johnson & Johnson).
- Linkedin account: https://bit.ly/3EvE9u1
- Healthcare engineer (Master's degree in healthcare engineering, medical devices option, Montpellier, DEDIENNE SANTÉ)
- Expertise in medical device (or healthcare product) design
- Specialized in biodegradable polymers and active ingredient release
- Linkedin account: https://bit.ly/3LfIgOD
- Student at ESSCA business school, Master international Business
- Professional experience in the Medtech world (Johnson & Johnson)
- Linkedin account: https://bit.ly/3ZgllbS
Dianosic is supporting by a solid network of partners to fuel company's growth.
Dianosic is backed by a Corporate partner (Aptar, US, a worldwide leader in the field of intranasal drug-delivery solutions), Venture Capital firms (Noshaq, Belgium; Capital Grand Est and Finovam, France, Clery, France and AKWA, Morocco) and by Business Angels.
Beside this, Dianosic is supported by Bpifrance, Banque Populaire and Caisse d’Epargne as well as the Fondation Force (France). Other key partners are : Quest For Health, Region Grand Est, Biovalley France, Conectus and the Eurometropole.
